Floatz logo

su011248

Progressive Hairy Cell Leukemia, Initial Treatment

National Cancer Institute (NCI)Phase 2Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Progressive Hairy Cell Leukemia, Initial Treatment cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Kite, A Gilead Company
Phase 2BB
Cediranib
Alexey Danilov, MD
Phase 1/2B
Fludarabine
Kite, A Gilead Company
Phase 2B
DEXAMETHASONE
City of Hope Medical Center
Phase 1/2B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Acerta Pharma BV
Phase 1/2B

View all 25 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →